Latest Breaking News On - Nathan dowden - Page 1 : vimarsana.com

Entrada Therapeutics, Inc : Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Entrada Therapeutics, Inc : Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesNathan dowdenKarla macdonaldKevin healyDipal doshiStefan klotterEntrada therapeutics incHealth canadaCompany endosomal escape vehicleExchange commissionResearch development rd expensesCorporate affairsVertex pharmaceuticalsHealthcare products regulatory agencyRegulatory affairs

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesKarla macdonaldNathan dowdenDipal doshiKevin healyHealthcare products regulatory agencyVertex pharmaceuticalsCorporate affairs officerCompany endosomal escape vehicleResearch development rd expensesExchange commissionRegulatory affairsEntrada therapeutics incHealth canadaTherapeutics reports fourth quarter

Entrada Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics

United statesDipal doshiKarla macdonaldNathan dowdenCorporate affairs officerHealthcare life sciences conferenceHealth care conferenceEntrada therapeutics incEndosomal escape vehicleAnnual healthcare life sciencesChief executive officerAnnual health careChief operating officerOrphan boneNeuromuscular diseasesInvestor relations

Entrada Therapeutics Appoints Dr Peter Kim to its Board of Directors

Posted on 290 Entrada Therapeutics, a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the appointment of Peter S. Kim, Ph.D., to its Board of Directors. “Dr. Kim is a pioneering scientist with over 30 years of experience in both academia and the biopharmaceutical industry,” stated Dipal Doshi, President and CEO of Entrada Therapeutics. “He has been recognized with countless honors, awards and appointments throughout the course of his career and we are extraordinarily fortunate to welcome him to our Board of Directors. Dr. Kim’s scientific and drug development expertise and experience will contribute to Entrada’s success in developing groundbreaking therapies.”

United statesWhitehead institutePeters kimChan zuckerberg biohubFelicia vonellaNathan dowdenAulani capuchinKush parmarDipal doshiInvestigator of the infectious disease initiativeCompany contactO groupNational academy of medicineNational academy of sciencesNational academy of engineeringAmerican academy of microbiology